CDC Website CDC Website

To Join the NPIN community or

You are here

Commercial Organizations

Ending the HIV Epidemic: A Plan for America Systems Coordination Provider

The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2020 for Ending the HIV Epidemic: A Plan for America –Technical Assistance Provider (HRSA-20-079) and Ending the HIV Epidemic: A Plan for America – Systems Coordination Provider (HRSA-20-089).

Ending the HIV Epidemic: A Plan for America Technical Assistance Provider

The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2020 for Ending the HIV Epidemic: A Plan for America –Technical Assistance Provider (HRSA-20-079) and Ending the HIV Epidemic: A Plan for America – Systems Coordination Provider (HRSA-20-089).

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines. 
 

Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals.

Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

Edith Jickling's picture

NIDA is interested in research that addressing research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited.

HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Clinical Trials Units (CTUs) to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. 

Pages

Subscribe to RSS - Commercial Organizations